CMIC：2019年亚洲临床试验报告（英文版）

there is no longer any excuse not toinclude japan as an integral part of anyglobal clinical-development programfor either pharmaceuticals or medicaldevices. With a more receptive climatefor both starting and running trials, an improvedinfrastructure for clinical research, and significantadvances in accelerating drug approvals,Japan isnow firmly on the global development map.

There have always been strong reasons to securea foothold in japan. lt is the world's third-largestsingle pha